| Literature DB >> 20186324 |
Yupin Suputtamongkol1, Wirichada Pongtavornpinyo, Yoel Lubell, Chuanpit Suttinont, Siriwan Hoontrakul, Kriangsak Phimda, Kitti Losuwanaluk, Duangjai Suwancharoen, Saowaluk Silpasakorn, Wirongrong Chierakul, Nick Day.
Abstract
BACKGROUND: Symptoms and signs of leptospirosis are non-specific. Several diagnostic tests for leptospirosis are available and in some instances are being used prior to treatment of leptospirosis-suspected patients. There is therefore a need to evaluate the cost-effectiveness of the different treatment strategies in order to avoid misuse of scarce resources and ensure best possible health outcomes for patients.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20186324 PMCID: PMC2826401 DOI: 10.1371/journal.pntd.0000610
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1The decision model showing each of the treatments and diagnostic options (first five branches).
The square at the far left of the diagram represents a decision node, with each branch representing the clinical management choices. The brackets indicate that patients who received each of the strategies proceeded to the subtree to the right. The circles at the start of each subsequent branching indicate chance nodes representing the uncertainty surrounding possible subsequent outcomes indicated in the branches to the right. This diagram shows the portion of the decision tree modeling the management strategies, the prevalence of leptospirosis, and diagnostic test performance (sensitivity and specificity).
Values and sources of inputs used in the decision model.
| Input | Base Case Value, % |
| Leptospirosis prevalence | 26 |
| Antibiotic side effect (rate) | 24.3 |
| Complication due to untreated leptospirosis | 10 |
| Complication due to untreated rickettsial infection | 10 |
| Complication due to other undifferentiated untreated illnesses | 8.4 |
Test performance using acute sera [10],[14].
| Test | Base case | Sensitivity Analysis Range | |
| (Lower bound) | (Upper bound) | ||
|
| |||
| Sensitivity | 0.34 | - | 0.70 |
| Specificity | 0.88 | 0.83 | 0.95 |
|
| |||
| Sensitivity | 0.36 | 0.26 | 0.81 |
| Specificity | 0.91 | 0.73 | 0.95 |
|
| |||
| Sensitivity | 0.51 | 0.35 | 0.74 |
| Specificity | 0.73 | 0.60 | 0.95 |
Outcome of treatment.
| Data Distribution | Base Case Value, day (SD) | Sensitivity Analysis Value | ||
| In leptospirosis | Duration of fever with doxycycline treatment | Normal | 2.04 (1.04) | 0.33–4.92 |
| Duration of fever without doxycycline treatment | Normal | 5.4 (0.3) | - | |
| In non-leptospirosis: Rickettsial infection | Duration of fever with doxycycline treatment | Lognormal | 1.62(0.67) | 0.5–4.5 |
| In non-leptospirosis: Others | Duration of fever with doxycycline treatment | Lognormal | 2.67 (2.46) | 0.33–15.8 |
| Duration of fever without doxycycline treatment | Normal | 5.3 (1.3) | - |
Costs (USD).
| Base Case Value, USD | |
| Doxycycline prescription | 2 |
| Lateral flow test | 5.7 |
| MCAT | 5.7 |
| Latex test | 5.7 |
| Doxycycline side effect, per day | |
| - no work loss | 2.9 |
| - work loss | 5.25 |
| Disease outcome (at end of 7-day course) | |
| - Cure | 0 |
| - Sick (daily cost of work loss from leptospirosis) | 5.25 |
| - Serious complication | 341 |
Cost of doxycycline (100 mg) 14 capsules in Thailand
Cost as of 2004 of lateral flow, MCAT, latex test.
Treatment of side effect symptoms such as antiemetic drug or antihistamine for rash.
With work loss, 1 day at minimum earning (5.25 USD) assumed.
There is no additional cost to patients not receiving antibiotics or to being cured.
Estimate of hospital costs, including intravenous antibiotics, other treatment.
Costs, clinical outcomes and antibiotic prescription at various prevalence rates and for patients receiving no treatment, empirical treatment, diagnosis using the latex test and diagnosis with a test with 95% sensitivity and specificity.
| Average cost/patient (USD) | Health outcomes | Doxycycline Prescriptions | ||||
| Duration of fever (Patients with fever at D7, %) | Patients with side effect, % | Patients with complications, % | Patients without leptospirosis given doxycycline, % | Patients with leptospirosis not given doxycycline, % | ||
|
| ||||||
| No antibiotic Rx | 13.3 | 5.35 (5.8) | 0 | 9.3 | 0 | 100 |
| Empirical Rx | 2.7 | 2.29 (1.7) | 24 | 0 | 100 | 0 |
| Latex test | 15.7 | 4.44 (4.6) | 7 | 6.47 | 27 | 49 |
| High accuracy test | 17.22 | 4.88 (5.54) | 3 | 7.7 | 5 | 5 |
|
| ||||||
| No antibiotic Rx | 13.3 | 5.35 (4.7) | 0 | 9.3 | 0 | 100 |
| Empirical Rx | 2.7 | 2.24 (1.3) | 24 | 0 | 100 | 0 |
| Latex test | 15.4 | 4.30 (3.8) | 8 | 6.2 | 27 | 49 |
| High accuracy test | 15.75 | 4.38 (4.53) | 7 | 6.5 | 5 | 5 |
|
| ||||||
| No antibiotic Rx | 13.3 | 5.35 (4.26) | 0 | 9.3 | 0 | 100 |
| Empirical Rx | 2.7 | 2.22 (1.22) | 24 | 0 | 100 | 0 |
| Latex test | 15.25 | 4.23 (3.42) | 9 | 6.0 | 27 | 49 |
| High accuracy test | 14.93 | 4.14 (4.07) | 9 | 5.8 | 5 | 5 |
Benefit-cost ratios for the different strategies.
| Strategy | Direct costs (USD) | Productivity loss (USD) | Benefit-cost ratio |
| No –antibiotic- treatment | 13.26 | 28.4 | (Baseline) |
| Empirical treatment | 2.70 | 11.8 | −1.57 |
| Latex test | 15.41 | 22.6 | 2.68 |
| Lateral flow test | 17.30 | 25.5 | 0.71 |
| MCAT | 17.23 | 25.4 | 0.75 |
*: The negative value is a result of the empirical treatment strategy being both less expensive and more effective than the no –antibiotic- treatment baseline